Moxifloxacin Abz (Moxifloxacin)

Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This blockade prevents bacterial DNA synthesis, leading to bacterial cell death and resolution of the infection.

The prescribed dose of moxifloxacin is determined by the treating clinician based on the type and severity of infection, patient age, weight, renal function and other clinical factors. Typical adult regimens often involve a once‑daily oral dose, but exact dosing must follow the prescriber’s order.

The safety of moxifloxacin during pregnancy and lactation has not been established; its pregnancy category is listed as unknown. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and only after discussion with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and enhanced activity against atypical respiratory pathogens compared with older fluoroquinolones such as levofloxacin. It also has a higher potency for certain anaerobes, but shares the class‑wide safety considerations, including tendon and QT‑interval risks.

Moxifloxacin Abz tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in damp or excessively hot environments.

Moxifloxacin Abz is taken orally as a tablet. The tablet should be swallowed whole with a full glass of water. It may be taken with or without food, but patients should follow any specific instructions provided by their prescriber.

Serious risks include tendon rupture (especially the Achilles tendon), QT‑interval prolongation leading to potentially life‑threatening arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and hepatic injury. Patients should be advised to seek immediate medical attention if they experience symptoms related to these conditions.

Moxifloxacin is contraindicated in individuals with a known hypersensitivity to moxifloxacin or any fluoroquinolone, those with a history of tendon disorders related to fluoroquinolone therapy, patients taking other QT‑prolonging drugs without careful monitoring, and individuals with certain cardiac conditions that predispose them to arrhythmias.